ITCI Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of -8.48% compared to Intra-Cellular Therapies's net margin of 15.24%. Intra-Cellular Therapies's return on equity of -8.07% beat Johnson & Johnson's return on equity of 19.98%.

Intra-Cellular Therapies has a consensus price target of $132.00, signalling upside risk potential of 0.56%. On the other hand Johnson & Johnson has an analysts' consensus of $169.07 which suggests that it could grow by 3.84%. Given that Johnson & Johnson has higher upside potential than Intra-Cellular Therapies, analysts believe Johnson & Johnson is more attractive than Intra-Cellular Therapies.

Intra-Cellular Therapies has a beta of 0.695, which suggesting that the stock is 30.512% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.473, suggesting its less volatile than the S&P 500 by 52.686%.

Intra-Cellular Therapies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.05% to investors and pays a quarterly dividend of $1.24 per share. Intra-Cellular Therapies pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Intra-Cellular Therapies quarterly revenues are $199.2M, which are smaller than Johnson & Johnson quarterly revenues of $22.5B. Intra-Cellular Therapies's net income of -$16.9M is lower than Johnson & Johnson's net income of $3.4B. Notably, Intra-Cellular Therapies's price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 28.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intra-Cellular Therapies is 19.89x versus 4.45x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of -8.48% compared to Intra-Cellular Therapies's net margin of 32.59%. Intra-Cellular Therapies's return on equity of -8.07% beat Eli Lilly and's return on equity of 80.24%.

Intra-Cellular Therapies has a consensus price target of $132.00, signalling upside risk potential of 0.56%. On the other hand Eli Lilly and has an analysts' consensus of $1,006.63 which suggests that it could grow by 23.74%. Given that Eli Lilly and has higher upside potential than Intra-Cellular Therapies, analysts believe Eli Lilly and is more attractive than Intra-Cellular Therapies.

Intra-Cellular Therapies has a beta of 0.695, which suggesting that the stock is 30.512% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.817%.

Intra-Cellular Therapies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.66% to investors and pays a quarterly dividend of $1.50 per share. Intra-Cellular Therapies pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Intra-Cellular Therapies quarterly revenues are $199.2M, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Intra-Cellular Therapies's net income of -$16.9M is lower than Eli Lilly and's net income of $4.4B. Notably, Intra-Cellular Therapies's price-to-earnings ratio is -- while Eli Lilly and's PE ratio is 69.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intra-Cellular Therapies is 19.89x versus 16.33x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Moderna has a net margin of -8.48% compared to Intra-Cellular Therapies's net margin of -117.16%. Intra-Cellular Therapies's return on equity of -8.07% beat Moderna's return on equity of -29.09%.

Intra-Cellular Therapies has a consensus price target of $132.00, signalling upside risk potential of 0.56%. On the other hand Moderna has an analysts' consensus of $54.40 which suggests that it could grow by 57.13%. Given that Moderna has higher upside potential than Intra-Cellular Therapies, analysts believe Moderna is more attractive than Intra-Cellular Therapies.

Intra-Cellular Therapies has a beta of 0.695, which suggesting that the stock is 30.512% less volatile than S&P 500. In comparison Moderna has a beta of 1.863, suggesting its more volatile than the S&P 500 by 86.269%.

Intra-Cellular Therapies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intra-Cellular Therapies pays -- of its earnings as a dividend. Moderna pays out -- of its earnings as a dividend.

Intra-Cellular Therapies quarterly revenues are $199.2M, which are smaller than Moderna quarterly revenues of $956M. Intra-Cellular Therapies's net income of -$16.9M is higher than Moderna's net income of -$1.1B. Notably, Intra-Cellular Therapies's price-to-earnings ratio is -- while Moderna's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intra-Cellular Therapies is 19.89x versus 4.20x for Moderna. Usually stocks with elevated PS ratios are considered overvalued.

Sage Therapeutics has a net margin of -8.48% compared to Intra-Cellular Therapies's net margin of -747.33%. Intra-Cellular Therapies's return on equity of -8.07% beat Sage Therapeutics's return on equity of -63.59%.

Intra-Cellular Therapies has a consensus price target of $132.00, signalling upside risk potential of 0.56%. On the other hand Sage Therapeutics has an analysts' consensus of $8.05 which suggests that it could grow by 4.22%. Given that Sage Therapeutics has higher upside potential than Intra-Cellular Therapies, analysts believe Sage Therapeutics is more attractive than Intra-Cellular Therapies.

Intra-Cellular Therapies has a beta of 0.695, which suggesting that the stock is 30.512% less volatile than S&P 500. In comparison Sage Therapeutics has a beta of 0.817, suggesting its less volatile than the S&P 500 by 18.337%.

Intra-Cellular Therapies has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sage Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intra-Cellular Therapies pays -- of its earnings as a dividend. Sage Therapeutics pays out -- of its earnings as a dividend.

Intra-Cellular Therapies quarterly revenues are $199.2M, which are larger than Sage Therapeutics quarterly revenues of $12.8M. Intra-Cellular Therapies's net income of -$16.9M is higher than Sage Therapeutics's net income of -$95.8M. Notably, Intra-Cellular Therapies's price-to-earnings ratio is -- while Sage Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intra-Cellular Therapies is 19.89x versus 11.37x for Sage Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.